ArticleScientific reports2020
DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs).
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Impact of aging on animal models of Parkinson's disease.Frontiers in aging neuroscience · 2022Pooled it
- Mendelian randomization study of genetic interactions between Alzheimer disease and celiac disease.Medicine · 2026Article
- Loss of Parkinson Disease Protein 7 (PARK7) upregulates ROS and cell migration and is associated with recurrent pregnancy loss.Molecular medicine (Cambridge, Mass.) · 2025Article
- The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson's disease mouse model.NPJ Parkinson's disease · 2025Article
- Multi-omics analysis highlights the link of aging-related cognitive decline with systemic inflammation and alterations of tissue-maintenance.bioRxiv : the preprint server for biology · 2025Article
- The role of gut-derived short-chain fatty acids in Parkinson's disease.Neurogenetics · 2024Review
- Metabolic fingerprinting by nuclear magnetic resonance of hepatocellular carcinoma cells during p53 reactivation-induced senescence.NMR in biomedicine · 2024Article
- A reduced proteomic signature in critically ill Covid-19 patients determined with plasma antibody micro-array and machine learning.Clinical proteomics · 2024Article
- Human genetic associations of the airway microbiome in chronic obstructive pulmonary disease.Respiratory research · 2024Article
- Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease.Molecular neurodegeneration · 2023Article
- New Pieces for an Old Puzzle: Approaching Parkinson's Disease from Translatable Animal Models, Gut Microbiota Modulation, and Lipidomics.Nutrients · 2023Review
- Shifts in Intestinal Metabolic Profile Among Kidney Transplantation Recipients with Antibody-Mediated Rejection.Therapeutics and clinical risk management · 2023Article
- Short Chain Fatty Acid Metabolism in Relation to Gut Microbiota and Genetic Variability.Nutrients · 2022Review
- Quantifying the role of transcript levels in mediating DNA methylation effects on complex traits and diseases.Nature communications · 2022Article
- Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop.Current neurology and neuroscience reports · 2022Review
- Gut microenvironmental changes as a potential trigger in Parkinson's disease through the gut-brain axis.Journal of biomedical science · 2022Review
- PARK7/DJ-1 as a Therapeutic Target in Gut-Brain Axis Diseases.International journal of molecular sciences · 2022Review
- Immune Response Modifications in the Genetic Forms of Parkinson's Disease: What Do We Know?International journal of molecular sciences · 2022Review
- Roux-En-Y Gastric Bypass (RYGB) Surgery during High Liquid Sucrose Diet Leads to Gut Microbiota-Related Systematic Alterations.International journal of molecular sciences · 2022Article
- Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proper communication between gut and brain is pivotal for the maintenance of health and, dysregulation of the gut-brain axis can lead to several clinical disorders. In Parkinson's disease (PD) 85% of all patients experienced constipation many years before showing any signs of motor phenotypes. For differential diagnosis and preventive treatment, there is an urgent need for the identification of biomarkers indicating early disease stages long before the disease phenotype manifests. DJ-1 is a chaperone protein involved in the protection against PD and genetic mutations in this protein have been shown to cause familial PD. However, how the deficiency of DJ-1 influences the risk of PD remains incompletely understood. In the present study, we provide evidence that DJ-1 is implicated in shaping the gut microbiome including; their metabolite production, inflammation and innate immune cells (ILCs) development. We revealed that deficiency of DJ-1 leads to a significant increase in two specific genera/species, namely Alistipes and Rikenella. In DJ-1 knock-out (DJ-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.